Cargando…

Systematic review comparing LABA, olodaterol, and indacaterol: limitations

Detalles Bibliográficos
Autor principal:	Donohue, James F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266268/ https://www.ncbi.nlm.nih.gov/pubmed/25525350 http://dx.doi.org/10.2147/COPD.S74766

Ejemplares similares

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
por: Rebordosa, Cristina, et al.
Publicado: (2020)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
por: van Zyl-Smit, Richard N., et al.
Publicado: (2023)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
por: Hsieh, Meng-Jer, et al.
Publicado: (2022)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
por: Plate, Tanja, et al.
Publicado: (2020)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Factors Associated with Indacaterol Response in Tuberculosis-Destroyed Lung with Airflow Limitation
por: Kim, Tae Hoon, et al.
Publicado: (2019)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2017)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease
por: Yamada, Hideyasu, et al.
Publicado: (2017)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
por: Watz, Henrik, et al.
Publicado: (2020)

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021)

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework
por: Chen, Chun-Yu, et al.
Publicado: (2023)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2a9ueqjd1bj233cd3ihn6cteao